Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:7177 |
Name | anal canal squamous cell carcinoma |
Definition | An anal canal cancer that derives_from epithelial squamous cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer anal canal cancer anal canal squamous cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
CD274 positive | Pembrolizumab | anal canal squamous cell carcinoma | predicted - sensitive | detail... |
CD274 positive | Retifanlimab | anal canal squamous cell carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02314169 | Phase II | Nivolumab | Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal | Active, not recruiting | USA | CAN | 0 |
NCT02879162 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | Active, not recruiting | CAN | 0 |
NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03597295 | Phase II | Retifanlimab | A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy | Completed | USA | ITA | FRA | ESP | DEU | BEL | 3 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Recruiting | USA | ESP | CAN | BEL | 0 |
NCT04230759 | Phase II | Durvalumab + Fluorouracil + Mitomycin C Fluorouracil + Mitomycin C | Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group (RADIANCE) | Recruiting | DEU | 1 |
NCT04357873 | Phase II | Pembrolizumab + Vorinostat | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations (PEVOsq) | Active, not recruiting | FRA | 0 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04989387 | Phase I | INCA00186 + Retifanlimab INCA00186 + INCB106385 INCA00186 + INCB106385 + Retifanlimab INCA00186 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | Recruiting | USA | ESP | BEL | AUT | 2 |
NCT05661188 | Phase II | Atezolizumab + Tiragolumab Cisplatin + Fluorouracil | Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS) (TIRANUS) | Not yet recruiting | ESP | 0 |